Mechanism of Action
Amylin Receptor System
Amylin receptors are heterodimers of the calcitonin receptor (CTR) with receptor activity-modifying proteins 1, 2, or 3 (RAMP1, 2, 3). These complexes are expressed in the area postrema, nucleus accumbens, hypothalamus, and peripheral tissues. Receptor activation raises cAMP and modulates ion channels, producing the characteristic effects on glucagon secretion, gastric motility, and food intake.
Metabolic Coordination with Insulin
Amylin and insulin are co-secreted in a ~1:100 molar ratio. While insulin lowers blood glucose by promoting cellular uptake, amylin prevents excessive glucose excursions by: (1) suppressing alpha-cell glucagon secretion; (2) slowing gastric emptying, reducing the rate of carbohydrate absorption; and (3) activating area postrema neurons to signal satiety and reduce meal size. This triad of actions prevents the wide postprandial glucose swings seen when amylin is absent.
Research Summary
Diabetes and Glycemic Control
Clinical Validation (via Pramlintide)Pramlintide (Symlin) trials in T1D and T2D demonstrated HbA1c reductions of 0.3-0.7% on top of optimized insulin therapy, with additional benefits of reduced insulin dose requirements, postprandial glucose excursion reduction, and modest weight loss of 1-2 kg. Effect size is smaller than GLP-1 agonists, but amylin analogs offer a complementary mechanism distinct from GLP-1 receptor agonism.
Obesity (CagriSema Combination)
Phase 3Cagrilintide, a long-acting amylin analog, in combination with semaglutide (CagriSema) produces 22-26% weight loss in Phase 2/3 trials -- among the highest for any pharmacological approach. This validates the amylin pathway as a powerful complement to GLP-1 receptor agonism for obesity management. See cagrilintide entry for full data.
Islet Amyloid and Beta Cell Toxicity
Active ResearchNative human amylin spontaneously aggregates into cytotoxic oligomers and amyloid fibrils. These deposits are present in >90% of T2D patients at autopsy and contribute to progressive beta cell loss. Strategies to prevent amylin aggregation -- small molecule inhibitors, analog design, and antibody-based clearance -- are active research areas to slow T2D progression.
Calculate your Amylin dose Vial strength, BAC water, exact syringe draw in IU. Free, no signup. Open Calc →
Research Protocols
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Postprandial glucose research | 1-5 pmol/kg/min IV infusion during meal studies (research) | Per meal study | Intravenous |
| Appetite/satiety research | 0.3-1 nmol/kg SC or ICV in rodent models | Per experiment | Subcutaneous or ICV |
Native amylin aggregates rapidly in solution; not used clinically. Pramlintide (Symlin) is the clinical amylin analog; see separate pramlintide entry for dosing.
Interactions
Safety Profile
Native amylin aggregates and is not used clinically (cytotoxic oligomers). Pramlintide analog safety profile: nausea is the most common effect (28% in T1D), usually transient with dose titration. Severe hypoglycemia risk when co-administered with insulin without dose adjustment. No pancreatitis association. Pramlintide is contraindicated in patients with hypoglycemia unawareness. The pathological aggregation of native amylin in islets is a disease mechanism rather than a drug safety issue.
References
- [1]Cooper GJ, et al. Purification and characterization of a peptide from amyloid-rich pancreases of type 2 diabetic patients. Proc Natl Acad Sci USA. 1987;84(23):8628-8632.
- [2]Ratner RE, et al. Amylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycaemic and weight control in Type 1 diabetes mellitus. Diabet Med. 2004;21(11):1204-1212.